Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 251 - 300 out of 15,686

Document Document Title
WO/2012/120044A1
The invention refers to TFEB related molecules, as variants, mutants, truncated proteins,chimeras etc. that are constitutively localized in the nucleus of a eukaryote cell. Such molecules have a therapeutic applicability in all of disord...  
WO/2012/122414A2
A linear dispensing system is provided that includes a plurality of channels, a pair of parallel rails, a plurality of carriers and a plurality of linear motor modules. The channels are configured to hold inventory products at an orienta...  
WO/2012/120048A1
The invention refers to TFEB phosphorylation inhibitors. Such molecules have a therapeutic applicability in all disorders that need induction of the cell authophagic/lysosomal system, such as lysosomal storage disorders, neurodegenerativ...  
WO/2012/121403A1
Problem: An object of the present invention is to provide a drug effective for the treatment of ALS, or a method for treating ALS. Solution: The present invention provides an ALS treatment method that improves clinical symptoms of ALS or...  
WO/2012/119074A1
The invention generally relates to systems, devices, apparatuses and methods for organizing cells in three-dimensions using matrix stiffness gradients. In particular, the invention relates to systems, devices, apparatuses and methods for...  
WO/2012/116176A2
Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general formula (I).  
WO/2012/112919A1
The invention relates to inhibition of SDF-la expression in subacromial bursa cells by CXCR-4 inhibitors. Bursal cell migration in response to SDF-α stimulation is also decreased in the presence of CXCR4 inhibitors. Accordingly, provide...  
WO/2012/112492A1
This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this inv...  
WO/2012/109296A1
Embodiments of the present invention are directed generally to antisense compounds and compositions for the treatment of muscular dystrophy, and in particular, Duchenne muscular dystrophy (DMD). In one embodiment, the invention is direct...  
WO/2012/109570A1
The present invention provides AAV capsid proteins, virus capsids comprising said capsid proteins and virus vectors comprising said capsid proteins, wherein the AAV capsid proteins have one or more mutations, wherein the mutation(s) resu...  
WO/2012/108478A1
The present invention is a compound represented by formula (I) (in the formula, each of the reference numerals is as recited in the specification) or a salt thereof.  
WO/2012/104823A3
The present invention relates to pyridopyrimidinone compounds of formula (I) for use in the treatment of neurodegenerative diseases.  
WO/2012/100389A1
Disclosed are a series of pentacyclic triterpenoid compounds, preparation methods and uses thereof. The compounds have anti-inflammatory, anti-tumor, anti-bacterial and antiviral activities, and they can be used for treating urinary inco...  
WO/2012/100408A1
A dextrin inclusion complex of total ginsenoside and total flavone of epimedium and the preparation method thereof are disclosed. A pharmaceutical formulation comprising the dextrin inclusion complex and the use of the dextrin inclusion ...  
WO/2012/100050A1
The present invention relates to a novel composition comprising an implant, scaffold or construct bound to a biological or chemical moiety. The bound moiety has the ability to bind to a component of the extracellular matrix of biological...  
WO/2012/098387A1
There is provided compounds of formula I, wherein R1, R2, R3 and R4 (and the -CH2-CH2 moiety) have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful i...  
WO/2012/097057A2
Compositions, methods and kits are provided for modulating the trans-differentiation of cells for example muscle satellite cells. The compositions, methods and kits include a modulator of trans-differentiation of the muscle satellite cel...  
WO/2012/096458A3
Provided are a process for the preparation of phenyl carbamate derivatives, useful in the treatment of CNS (central nervous system) disorders, an intermediate in the synthesis of the phenyl carbamate derivatives, and a process for prepar...  
WO/2012/097093A2
The invention provides novel Wnt polypeptides that have enhanced solubility and improved biologic drug-like properties, and polynucleotides encoding the Wnt polypeptides of the invention. The Wnt polypeptides of the invention can be used...  
WO/2012/095853A1
The present invention relates to a pharmaceutical composition for oral administration which comprises an active pharmaceutical ingredient ("API") selected from SIP receptor modulators and agonists, wherein the composition is adapted to p...  
WO/2012/097330A2
Methods and compositions for treating degenerative muscle conditions are disclosed. The compositions disclosed herein include S1P promoting compositions that include an S1P promoting agent. In certain embodiments disclosed herein, the S1...  
WO/2012/096458A2
Provided are a process for the preparation of phenyl carbamate derivatives, useful in the treatment of CNS (central nervous system) disorders, an intermediate in the synthesis of the phenyl carbamate derivatives, and a process for prepar...  
WO/2012/097057A3
Compositions, methods and kits are provided for modulating the trans-differentiation of cells for example muscle satellite cells. The compositions, methods and kits include a modulator of trans-differentiation of the muscle satellite cel...  
WO/2012/097330A3
Methods and compositions for treating degenerative muscle conditions are disclosed. The compositions disclosed herein include S1P promoting compositions that include an S1P promoting agent. In certain embodiments disclosed herein, the S1...  
WO/2012/097093A3
The invention provides novel Wnt polypeptides that have enhanced solubility and improved biologic drug-like properties, and polynucleotides encoding the Wnt polypeptides of the invention. The Wnt polypeptides of the invention can be used...  
WO/2012/094636A2
Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory rec...  
WO/2012/092035A9
Disclosed are methods utilizing beta-hydroxy-beta-methylbutyrate (HMB) for facilitating the recovery of muscle after a period of muscle disuse. The HMB facilitates the recovery of muscle mass in an individual and can also be used to prev...  
WO/2012/091571A3
Composition comprising at least two components, more preferably at least three components, more preferably at least four components, selected from the group of (i) a nucleoside equivalent, (ii) an ω-3 polyunsaturated fatty acid selected...  
WO/2012/091549A1
Composition comprising at least two components, more preferably at least three com- ponents, more preferably at least four components, selected from the group of (i) a nu- cleoside equivalent, (ii) an ω-3 polyunsaturated fatty acid sele...  
WO/2012/088597A1
Use of nitric oxide amino acid esters to treat muscular or neuromuscular diseases, increase muscle growth and/or muscle strength, or to stimulate vasodilation prior to physical training. Preferred muscular or neuromuscular diseases are m...  
WO/2012/091542A1
Composition comprising at least two components, more preferably at least three components, more preferably at least four components, selected from the group of (i) a nucleoside equivalent, (ii) an ω-3 polyunsaturated fatty acid selected...  
WO/2012/092035A1
Disclosed are methods utilizing beta-hydroxy-beta-methylbutyrate (HMB) for facilitating the recovery of muscle after a period of muscle disuse. The HMB facilitates the recovery of muscle mass in an individual and can also be used to prev...  
WO/2012/091571A2
Composition comprising at least two components, more preferably at least three components, more preferably at least four components, selected from the group of (i) a nucleoside equivalent, (ii) an ω-3 polyunsaturated fatty acid selected...  
WO/2012/085586A1
The present invention concerns prodrugs of mexiletine (and mexiletine's active metabolite) pharmaceutical compositions containing such prodrugs. Methods for treating myotonic conditions, while reducing the inherent adverse G1 side effect...  
WO/2012/081570A1
Provided is a lactam compound or a salt thereof indicated by formula (1), which is a compound with a lactam skeleton or a salt thereof useful as a PPAR activator. [In the formula, the ring Z indicates a condensed hydrocarbon ring or a he...  
WO/2012/079057A2
A formulation comprising jasmonate for improving skeletal muscle function in a mammal, particularly a human is provided. This may be accomplished by reducing muscle fatigue and/or increasing skeletal muscle performance.  
WO/2012/079057A3
A formulation comprising jasmonate for improving skeletal muscle function in a mammal, particularly a human is provided. This may be accomplished by reducing muscle fatigue and/or increasing skeletal muscle performance.  
WO/2012/074068A1
Provided is an amplifier for hematopoietic stem cells and/or hematopoietic precursor cells having utility as a therapeutic method against types of hematopoietic disease, and having utility for improving gene transfer efficiency to the he...  
WO/2012/075462A2
The present disclosure provides methods for introducing a gene encoding a muscle membrane protein into a cell isolated from a subject to generate a genetically modified cell. The genetically modified cell may be introduced back, e.g., en...  
WO/2012/068981A1
Disclosed are 6-deoxy-6-thioether-amino acid cyclodextrin derivatives, obtained from condensation of amino acid derivatives with halo-cyclodextrin in the presence of a base. The 6-deoxy-6-thioether-amino acid cyclodextrin derivatives inc...  
WO/2012/067262A1
The present invention provides a therapeutic agent for diseases associated with skeletal muscle degeneration, which comprises a granular colony stimulation factor (G-CSF) as an active ingredient. This therapeutic agent is particularly ef...  
WO/2012/064090A9
The present invention provides a chemical preparation method of skeletal muscle-derived multipotent cells comprising: (a) a step for obtaining differentiated cells from mammals; and (b) a step for obtaining multipotent cells by treating ...  
WO/2012/064090A2
The present invention provides a chemical preparation method of skeletal muscle-derived multipotent cells comprising: (a) a step for obtaining differentiated cells from mammals; and (b) a step for obtaining multipotent cells by treating ...  
WO/2012/064090A3
The present invention provides a chemical preparation method of skeletal muscle-derived multipotent cells comprising: (a) a step for obtaining differentiated cells from mammals; and (b) a step for obtaining multipotent cells by treating ...  
WO/2012/058220A2
The present invention features anti-SODl antibodies and methods of using the antibodies for the treatment of amyotrophic lateral sclerosis (ALS) or the amelioration of symptoms associated with ALS.  
WO/2012/058220A3
The present invention features anti-SODl antibodies and methods of using the antibodies for the treatment of amyotrophic lateral sclerosis (ALS) or the amelioration of symptoms associated with ALS.  
WO/2012/054530A2
Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory rece...  
WO/2012/053994A2
The present disclosure relates to ecdysteroid analogues which have similar, identical, or enhanced biological activities as compared to brassinosteroids, for instance similar, identical, or enhanced plant growth promoting activity. The e...  
WO/2012/053012A3
The present invention relates to stable pharmaceutical compositions of thiocolchicoside comprising nano size droplets of thiocolchicoside or salts thereof along with other pharmaceutically acceptable excipients. The present invention als...  
WO/2012/054527A2
Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory rece...  

Matches 251 - 300 out of 15,686